ATYR aTyr Pharma, Inc.
Healthcare$0.48-1.16%ClosedMarket Cap: $47.5M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
0.83
P/S
252.87
EV/EBITDA
-0.70
DCF Value
$-0.04
FCF Yield
-123.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
-11754.7%
Operating Margin
-38573.7%
Net Margin
-36857.4%
ROE
-99.9%
ROA
-87.9%
ROIC
-105.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-11.4M | $-10.8M | $— | — |
| Q4 null | $0.00 | NaN% | $-14.8M | $-14.0M | $— | — |
| FY null | $190.0K | -717.4% | $-77.6M | $-74.1M | $— | — |
| Q3 null | $190.0K | -11547.4% | $-26.7M | $-25.7M | $— | — |
| Q2 null | $0.00 | NaN% | $-20.3M | $-19.5M | $— | — |
| Q1 null | $0.00 | NaN% | $-15.8M | $-14.9M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-15.8M | $-15.0M | $— | — |
| FY null | $235.0K | 100.0% | $-67.9M | $-64.0M | $— | — |
| Q3 null | $0.00 | NaN% | $-18.1M | $-17.3M | $— | — |
| Q2 null | $0.00 | NaN% | $-17.3M | $-16.3M | $— | — |
| Q1 null | $235.0K | 100.0% | $-16.6M | $-15.5M | $— | — |
| Q4 2023 | $0.00 | -Infinity% | $-16.0M | $-14.8M | $-0.25 | — |